To develop and evaluate a brief, easy-to-administer symptom assessment scale
for use as a preference-based outcome measure in clinical trials and cost-effectiveness studies in asthma.
Cross-sectional survey with 2-week reproducibility assessment.
Ambulatory care : university asthma and allergy center.
One hundred sixty-one adults with asthma, 59% female, mean age 35 ± 11 years.
Mean FEV1 percent predicted was 86 ± 17%. Interventions : The 11-item Asthma Symptom Utility Index (ASUI).
Mean ASUI score for this sample was 0.71 ± 0.23, with a range from 0.02 to 1.0. The ASUI was reproducible (intraclass correlation coefficient=0.74) and able to distinguish patients known to differ on disease severity according to clinician ratings (p<0.001) and by an asthma disease severity scale score (p<0.001).
The instrument was also significantly correlated with FEV1percent predicted (r=0.27, p<0.001), the Asthma Quality of Life Questionnaire (r=0.77, p<0.001), and the Health Utilities Index Mark 2 (r=0.36, p<0.001).
The results of this study support the reliability and validity of the ASUI, suggesting it will be a useful, complementary patient outcome measure for clinical trials and cost-effectiveness studies comparing treatment alternatives for persons with asthma.
Mots-clés Pascal : Asthme, Symptomatologie, Qualité vie, Analyse coût efficacité, Economie santé, Pronostic, Homme, Appareil respiratoire pathologie, Bronchopneumopathie obstructive
Mots-clés Pascal anglais : Asthma, Symptomatology, Quality of life, Cost efficiency analysis, Health economy, Prognosis, Human, Respiratory disease, Obstructive pulmonary disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0499298
Code Inist : 002B11B. Création : 19/02/1999.